688338 Stock Overview
Engages in the research and development, manufacture, and sale of in-vitro diagnostic products in China and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 2/6 |
Rewards
Risk Analysis
Beijing Succeeder Technology Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥22.40 |
52 Week High | CN¥36.38 |
52 Week Low | CN¥18.49 |
Beta | 0.44 |
11 Month Change | 5.56% |
3 Month Change | -6.12% |
1 Year Change | -28.39% |
33 Year Change | -38.80% |
5 Year Change | n/a |
Change since IPO | -82.89% |
Recent News & Updates
Shareholder Returns
688338 | CN Medical Equipment | CN Market | |
---|---|---|---|
7D | -2.0% | -2.8% | -1.1% |
1Y | -28.4% | -13.5% | -17.4% |
Return vs Industry: 688338 underperformed the CN Medical Equipment industry which returned -13.5% over the past year.
Return vs Market: 688338 underperformed the CN Market which returned -17.4% over the past year.
Price Volatility
688338 volatility | |
---|---|
688338 Average Weekly Movement | 4.6% |
Medical Equipment Industry Average Movement | 5.1% |
Market Average Movement | 5.5% |
10% most volatile stocks in CN Market | 8.9% |
10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 688338 has not had significant price volatility in the past 3 months.
Volatility Over Time: 688338's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 296 | Hai Wang | www.succeeder.com.cn |
Beijing Succeeder Technology Inc. engages in the research and development, manufacture, and sale of in-vitro diagnostic products in China and internationally. The company offers automatic detection instruments, including coagulation, hemorheology, hematocrit, and platelet aggregation, as well as supporting reagents and consumables. Its products are used in the prevention, screening, diagnosis, and monitoring of thrombophilia, coronary heart disease, venous thromboembolism, and other thrombotic and bleeding diseases.
Beijing Succeeder Technology Inc. Fundamentals Summary
688338 fundamental statistics | |
---|---|
Market cap | CN¥2.43b |
Earnings (TTM) | CN¥119.41m |
Revenue (TTM) | CN¥293.04m |
19.9x
P/E Ratio8.1x
P/S RatioIs 688338 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688338 income statement (TTM) | |
---|---|
Revenue | CN¥293.04m |
Cost of Revenue | CN¥107.49m |
Gross Profit | CN¥185.55m |
Other Expenses | CN¥66.13m |
Earnings | CN¥119.41m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 1.13 |
Gross Margin | 63.32% |
Net Profit Margin | 40.75% |
Debt/Equity Ratio | 0.007% |
How did 688338 perform over the long term?
See historical performance and comparison